about
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionCost-effectiveness of models for prevention of vertical HIV transmission - voluntary counseling and testing and choices of drug regimenMaraviroc: a review of its use in HIV infection and beyondCrystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse TranscriptaseHIV/AIDS epidemiology, pathogenesis, prevention, and treatmentThe challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaquesPersistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques.Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispeciesLow-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.Children and HIV/AIDS: from research to policy and action in resource-limited settingsEffectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in UgandaImpact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.Outcome of Different Nevirapine Administration Strategies in Preventin g Mother-to-Child Transmission (PMTCT) Programs in Tanzania and Uganda.Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
P2860
Q24672964-0B9ACD3C-0996-45E6-B44E-5B6CEEB3B009Q24815606-CBE3F9BB-9183-405E-AB6D-1D794CCC30E1Q26778504-94BC60EE-0931-4042-8C9B-51FE45729375Q27657535-BBDE4A25-9712-4803-A9CE-0CD89ACA51BCQ30356074-2CB2F585-B12A-429F-9585-91E918172ED8Q30425595-0154149A-0C5C-4DFB-85B9-0D4F5F924B64Q33972150-CF24D015-75B7-4892-B0EF-8448E2A44770Q34087809-F90B7915-55B9-4C8D-BD8F-13CE6FB916C4Q34112568-EE21BE2C-9DDF-4CB7-A41D-92FA70DDAF3FQ34151052-2019BEED-9E7C-42AF-A3B2-FFDC2F78ECDCQ34598577-FF889FBA-E8EF-4115-914A-333DAA4DCA85Q34982693-6B843E33-0D2C-4D6C-9C18-DD10A2616F4FQ35021860-46FAA9F6-BEE0-45E0-A71A-4ED09B2AB49CQ35473551-E1C31101-4D11-4793-9650-972C144642FAQ35947480-E69E245A-5AA5-468C-981F-5189F8D1F26DQ36060517-D68DB363-108E-44B0-B6F7-5B7D49A6225AQ37143745-A6341104-ABE6-42F1-8BC6-805BAEEFA25BQ37207234-3A21E308-4470-4E03-9509-74CD8212823EQ37304975-91DBCCCC-036D-4BDE-84E5-CE32B665AB50Q37381591-86A568BF-18A5-4871-B9B1-0B08F4D42FD0Q37730522-58149AB2-E11D-4D17-BB0D-48B172FE52F5
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Nevirapine resistance after single dose prophylaxis.
@ast
Nevirapine resistance after single dose prophylaxis.
@en
Nevirapine resistance after single dose prophylaxis.
@nl
type
label
Nevirapine resistance after single dose prophylaxis.
@ast
Nevirapine resistance after single dose prophylaxis.
@en
Nevirapine resistance after single dose prophylaxis.
@nl
prefLabel
Nevirapine resistance after single dose prophylaxis.
@ast
Nevirapine resistance after single dose prophylaxis.
@en
Nevirapine resistance after single dose prophylaxis.
@nl
P1433
P1476
Nevirapine resistance after single dose prophylaxis
@en
P2093
J Brooks Jackson
P577
2002-04-01T00:00:00Z